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ABSTRACT

Upstream Methods for Enhancing Engineered Curcumin Biosynthesis

by

Caleb D. Barton, Master of Science
Utah State University, 2022

Major Professor: Dr. Jixun Zhan
Department: Biological Engineering

Curcumin is an extremely versatile natural compound possessing several therapeutic
benefits ranging from anti-cancer potential to anti-Alzheimer’s properties. Though it occurs
naturally in the roots of Curcuma longa, curcumin may be biosynthesized in the heterologous host
Escherichia coli. However, insufficient amounts of curcumin have been obtained from the
heterologous system up to now.
Various upstream methods were employed to enhance the production of curcumin in an
engineered E. coli platform. First, the enzymatic approach for achieving curcumin biosynthesis
was optimized. Plant enzymes were explored in combination with bacterial enzymes to find the
most productive enzymatic approach. Specifically, the productivity of bacterial feruloyl-CoA
synthase (FCS) was compared with that of the plant 4-coumarate-CoA ligase (4CL), and
curcuminoid synthase (CUS) was compared with diketide-CoA synthase (DCS) and curcumin
synthase (CURS1). Additionally, the use of transferase co-expression systems was used to study
the effect of appending sugar or sulfate moieties to curcumin to enhance the water solubility and
thus facilitate its export from the cell, allowing for continuous fermentation and reducing the
cytotoxic effects of intracellular curcumin accumulation. Specifically, the use of a
glucosyltransferase from Beauveria bassiana, a glucuronyltransferase from Streptomyces
chromofuscus, and a sulfotransferase from Haliangium ochraceum and each of their impacts on
curcumin production was discussed.
(74 pages)
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PUBLIC ABSTRACT

Upstream Methods for Enhancing Engineered Curcumin Biosynthesis
Caleb D. Barton

Curcumin is a bright orange compound with myriad applications for human health and
wellness. Curcumin occurs naturally in the plant Curcuma longa (commonly known as turmeric)
but must be extracted from the roots in an environmentally unfriendly fashion to obtain
commercially relevant amounts of the compound. In addition, extraction of curcumin from
turmeric spice yields a mixture of various curcuminoids, presenting an issue for isolating it in its
pure form and complicating its use in clinical settings.
Heterologous biosynthetic production of curcumin in Escherichia coli has been used
extensively as a viable alternative to plant extraction but suffers from poor yield. This thesis
describes the application of various upstream biological engineering methods for enhancing the
production of curcumin in an engineered E. coli platform. Among these, the enzyme combination
for achieving curcumin biosynthesis is optimized, including the use of bacterial and plant enzymes
for improving the overall yield. Since curcumin is mainly produced as an intracellular metabolite
with cytotoxic effects on the production host, the use of a handful of transferases that can improve
curcumin water solubility is also explored to improve excretion from the cell.
These approaches led to the establishment of an efficient curcumin biosynthetic pathway,
the identification of several feruloyl-CoA synthases (FCSs) that may be used in place of 4coumarate-CoA ligase (4CL), and methods for improving curcumin excretion from the cell
together with more bioavailable curcumin derivatives. We also discuss the use of a bacterial longchain fatty acid-CoA ligase for the efficient production of a curcuminoid known as
dicinnamoylmethane.
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CHAPTER I
Introduction

The natural world contains an amazing repository of natural products that forms the basis
of many supplements, pharmaceuticals, and therapeutics in use today. Drug discovery and
development has often relied on biomolecules obtained from nature, beginning with the discovery
of penicillin in 1929 and continuing to the present day. Among these, the polyketide family is of
special interest. Polyketides are a group of acetate-derived, structurally diverse natural compounds
exhibiting a broad spectrum of bioactivities.1 These multi-faceted compounds can be derived from
plants, fungus, and bacteria. Polyketides are synthesized by polyketide synthases (PKSs), which
are generally multi-domain enzymes that can be categorized into three types. Type I PKSs are
large, modular enzymes that pass molecules through a series of catalytic domains, while Type II
PKSs are smaller and form multienzyme complexes capable of producing aromatic polyketides.
Type III PKSs form homodimers, and act in an iterative fashion to prime, extend, and cyclize their
targets.2
One member of the polyketide family is a health-promoting, aromatic plant polyketide
known as curcumin that is formed by the action of Type III plant PKSs.3 This bright orange
compound is commonly harvested from the rhizome of Curcuma longa (turmeric spice) together
with other aromatic polyketides that share a similar core structure, known as curcuminoids.
Curcuminoids (most especially curcumin) have been reported to possess myriad health benefits,
most importantly anticancer properties, making them interesting targets for pharmaceutical
research (Fig. 1.1).
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Figure 1.1: Chemical structure of a variety of curcuminoids

Ongoing academic and clinical studies on curcumin and other curcuminoids have created
an increased need for pure curcuminoid products and improved methods for their production and
isolation. Heterologous production of curcuminoids in Escherichia coli has garnered special
interest in the last several years but has not been able to produce commercially relevant titers of
the compounds for competing with the agricultural methods commonly used for their production.
Heterologous biosynthesis has several benefits over agricultural methods, including reduced time
scale, land use, and organic solvent consumption.
This thesis explores a variety of upstream biological engineering approaches to improving
heterologous curcuminoid biosynthesis in E. coli with special focus on curcumin. Herein, we
utilize several enzymatic approaches for enhancing engineered curcuminoid production. Among
these, we discuss the use of several enzymatic approaches employing combinations of both plant
and bacterial proteins to achieve curcumin biosynthesis. Specifically, we compare the use of
feruloyl-CoA synthase (FCS) in place of the 4-coumarate-CoA ligase (4CL) commonly used for
catalyzing the formation of feruloyl-CoA from ferulic acid. We also demonstrate the importance
of diketide-CoA synthase (DCS) as an important enzymatic factor for enhancing curcumin
production. We also make quantitative comparisons between the productivity of curcuminoid
synthase (CUS) and curcumin synthase (CURS1). Additionally, we explore methods for excreting
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curcumin from E. coli, which is produced primarily as an intracellular metabolite, exerting a
cytotoxic effect on the production host. These methods include glucosylation, glucuronidation,
and sulfation to assist in the development of continuous fermentation production processes.
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CHAPTER II
Literature Review

2.1 Medical Relevance of Curcumin
Curcumin has long been known for its amazing therapeutic properties.4 Most notably
recognized for its anti-cancer,5 anti-inflammatory,6 antidiabetic,7 and anti-Alzheimer’s properties,8
curcumin is an important and multi-faceted drug target. Ongoing research continuously identifies
more therapeutic benefits of this “golden nutraceutical”.9 At the forefront of this research, a variety
of curcumin formulations have been successfully applied for the treatment of cancer cells and
tumors.10 Recent work has also shown that curcumin may be used for the treatment of age-related
disease.11
Relevant to the modern health crisis caused by the COVID-19 pandemic, patients infected
with SARS-CoV-2 who took curcumin orally exhibited significantly quicker recoveries in a
double-blind, randomized trial.12 The antiviral and antibacterial properties of curcumin have been
demonstrated for other important human pathogens as well, including the influenza virus, hepatitis
C virus, HIV, Zika virus, and strains of Staphylococcus, Streptococcus, and Pseudomonas.13
Curcumin acts against viruses by at least 8 distinct mechanisms: virus entry inhibition,14–20 particle
production inhibition,21 replication inhibition,22–24 cccDNA inhibition,25,26 protease inhibition,27
integrase inhibition,28 Tat protein inhibition,29 and gene expression inhibition.30,31 As an
antibacterial agent, curcumin acts as a growth inhibitor,32–36 biofilm formation inhibitor,37
adhesion inhibitor,38 and a Sortase A inhibitor of gram positive bacteria.39 Curcumin has
additionally been demonstrated to possess antifungal properties and acts by disrupting fungal
plasma membranes.40
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Curcumin has dual effects on angiogenesis, or the formation of blood vessels, exhibiting
both antiangiogenic and proangiogenic activities.41 The angiogenic effects of curcumin have been
the subject of much study to elucidate the exact impact curcumin may have on human vascular
health. On one hand, curcumin is an antiangiogenic compound by affecting the entire angiogenic
process through downregulation of NF-κB, an angiogenesis transcription factor, and VEGF, bFGF,
and some MMPs, proangiogenic factors that have been linked to tumor progression.42 On the other
hand, curcumin promotes neovascularization by upregulation of TGF-beta, which promotes wound
healing in adults.34,43,44 Together, these findings demonstrate that curcumin possesses powerful
pharmaceutical potential for balancing healthy angiogenesis, with potential applications ranging
from topical burn treatment 45 to tumor inhibition.46
Studies have also confirmed that curcumin has a regulatory effect on the gut microbiome,
preventing the myriad of health issues that can arise as a result of dysbiosis.47 Specifically,
curcumin selects for beneficial bacterial strains in the gastrointestinal tract, as was recently
confirmed by an in vivo study on duck gut microbiota.48 Genera that are linked to diabetes and
inflammation in individuals with high fat diets can similarly be counteracted by curcumin.49
Additionally, other disorders linked to intestinal microflora can likewise be regulated by oral
curcumin administration, including estrogen deficiency,50 memory loss,51 and some cancers.52
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Figure 2.1: Summary of the health-promoting properties of curcumin with selected modes of action listed in parentheses and
bulleted lists of target disorders being treated with curcumin formulations in clinical and academic studies.

Several curcumin products are already available on the market, including a variety of
curcumin-based topical ointments which are used to reduce pain caused by inflammation of the
joints, as in the case of arthritis. Bandages have also been developed with turmeric extract to
promote wound healing and reduce the risk of infection. Several oral supplements are also
available on the market, including curcumin nano-formulations and liposomal curcumin that are
designed to enhance curcumin bioavailability.
2.2 Curcumin Production and Isolation
Curcumin is traditionally obtained using high-energy input solvent extractions from the
roots of Curcuma longa, commonly known as turmeric spice.53 Traditional extraction methods are
not selective, and require the use of large amounts of toxic solvents.54 Though much work has been
done to improve the downstream processing of curcumin,55 no amount of downstream optimization
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can address the large time scale, extensive labor, and vast land required for the production of
curcumin in C. longa.
Heterologous biosynthesis of curcumin has garnered interest in recent years as a substitute
for agricultural methods. Heterologous biosynthesis addresses each of the aforementioned issues:
bioreactor and fermenter footprints are on the order of square feet rather than square miles,
automation has allowed most bioreactor use to require little hands-on management, and the time
required to achieve biosynthetic curcumin production requires hours rather than months.56
E. coli has been used most extensively as a host for heterologous curcumin biosynthesis.56–
60

However, recent methods have employed other hosts to attempt to improve production. One

study

61

aimed to improve the malonyl-CoA supply using Aspergillus oryzae as the production

host, with disruptions to snfA, which encodes an inhibitor of the acetyl-CoA carboxylase
responsible to produce malonyl-CoA from acetyl-CoA, and to SCAP, which encodes a sterol
regulatory-element binding protein cleavage-activating protein (SCAP) that utilizes acetyl-CoA
for sterol biosynthesis. Together, these techniques resulted in a six-fold improvement in curcumin
yield. Another study

62

used Saccharomyces cerevisiae as an engineered host for curcumin

production, demonstrating that the use of a rich medium, Type III PKSs, and suppressed ferulic
acid decarboxylase improved curcumin titers in the engineered strain. Most recently, the hairy
roots of Atropa belladonna, an herbaceous plant in the nightshade family, were successfully
engineered for curcuminoid biosynthesis.63 The use of A. belladonna allowed for the synthesis of
curcumin, curcumin glycosides, demethoxycurcumin and bisdemethoxycurcumin.
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2.3 Heterologous Curcumin Biosynthesis in E. coli
The heterologous biosynthetic production of curcumin in E. coli can be achieved by
feeding ferulic acid as a substrate, which is converted to feruloyl-CoA by a plant 4-coumarateCoA ligase (4CL).62 In almost all published literature, plant 4CLs are used for engineered
curcumin biosynthesis. We propose the use of a bacterial 4CL or FCS, which may exhibit higher
substrate specificity toward ferulic acid based on its name and function. Subsequently, feruloyl-

Figure 2.2: Two enzymatic approaches for achieving curcumin biosynthesis from ferulic acid.
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CoA is condensed with malonyl-CoA to form feruloyl-diketide-CoA either by diketide-CoA
synthase (DCS) or curcuminoid synthase (CUS). Two more condensation steps take place to form
curcumin by the action of either curcumin synthase (CURS1) or again by the curcuminoid synthase
(CUS)53,55,56,64 (Fig. 2.2). The conversion of ferulic acid to feruloyl-CoA may be alternatively
catalyzed by a feruloyl-CoA synthase (FCS), which is often observed in the vanillin biosynthetic
pathway. To our knowledge, no studies have been done to compare the efficiency of a bacterial
FCS or 4CL for curcumin biosynthesis against the plant 4CL currently in use for this pathway.
Specifically, the 4CL from Arabidopsis thaliana (4CL1) is most used for completing the reaction
in most published literature. In addition, no direct comparisons have been reported for the use of
DCS/CURS1 as opposed to CUS alone.
Other studies have also utilized tyrosine, coumaric acid, or caffeic acid as a starter substrate
for achieving curcumin biosynthesis.64,65 These approaches require more enzymatic steps to form
curcumin, namely the use of tyrosine ammonia lyase (TAL) to convert tyrosine into coumaric acid,
4-coumarate 3-hydroxylase (C3H) to convert coumaric acid into caffeic acid, and caffeic acid Omethyltransferase (COMT) to convert caffeic acid into ferulic acid.66 In addition, each of these
approaches can also be used to form other medically-important curcuminoids. For example, just
as curcumin can be formed enzymatically from ferulic acid; bisdemethoxycurcumin can be formed
from coumaric acid, dicaffeoylmethane from caffeic acid, and dicinnamoylmethane from cinnamic
acid 67 (Fig. 2.3). Several of these curcuminoids and others have also been demonstrated to exhibit
powerful activities benefitting human health.68
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Figure 2.3: Production of various curcuminoids from amino acid precursors
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Recent work has aimed to improve curcumin yields from heterologous systems by
optimizing the culture medium, expression host, carbon source concentration, and induction
parameters.56 In addition, co-culture systems have been employed to improve curcumin formation
by reducing the overall metabolic burden imposed on E. coli due to protein overexpression.64
These efforts have resulted in markedly improved curcumin yields but have not made clear
comparisons on the benefits of one enzymatic approach over another. Characterization of the
alternative enzymes that can be used in the curcumin biosynthetic pathway and a clear comparison
of their corresponding yields is needed to further contribute to the commercial relevance of
biosynthetic methods.
2.4 Curcumin Hydrophobicity and Cytotoxic Effect on Production Host
Curcumin is a hydrophobic compound that cannot easily traverse cell membranes,69
causing it to be mostly accumulated intracellularly in an engineered E. coli system.65,70 Some
metabolic engineering methods have been employed to facilitate the intracellular storage of
hydrophobic compounds such as curcumin,58 but little work has been done to investigate methods
for exporting curcumin from the cell.
The intracellular accumulation of curcumin in the engineered E. coli system poses an issue
for cell survival, since curcumin has been shown to have an apoptotic-like effect on E. coli.71,72
This effect reduces the number of cell factories available for producing curcumin, in turn reducing
the overall efficacy of the engineered system. Additionally, intracellular curcumin accumulation
of E. coli can greatly increase the downstream processing needed for product isolation due to the
need for cell disruption.73 Furthermore, excretion of curcumin from the cell could allow for the
use of continuous fermentation instead of batch or fill-and-draw operations. Continuous

12

fermentation has long been preferred over other fermentation methods and offers numerous
advantages, including: (1) reduced operating costs, (2) easier operational control, (3) yield
improvement, and (4) improved product consistency, among others.74
Glycosylation is a common method utilized for improving the solubility of natural
products, including curcumin.75 Curcumin that was O-methyl-glycosylated in an in vivo using the
fungal strain Beauveria bassania ATCC 7159 exhibited a 39,000-fold improvement in water
solubility over unmodified curcumin.76 Our group recently reported the discovery and
characterization of two transferases that were demonstrated to be capable of appending sugar
moieties to curcumin in vitro, namely a glucosyltransferase from the filamentous fungus Beauveria
bassania ATCC 7159 (BbGT) and a UDP-glucuronyltransferase from Streptomyces chromofuscus
ATCC 49982 (UGT).77,78 These enzymes are perfect candidates for testing in vivo glycosylation
of curcumin as a method of excreting curcumin from the cell.
Similar to glycosylation, the addition of sulfate to curcumin greatly enhances its water
solubility and bioavailability.79 In human metabolism, curcumin sulfation has been demonstrated
to enhance curcumin’s ability to permeate the cell membrane, resulting in greatly reduced
intracellular concentrations and higher curcumin titers in the culture media.80 This detoxification
mechanism allows the cell to control the overaccumulation of curcumin inside the cell. However,
to our knowledge, sulfation of curcumin has yet to be employed in an engineered E. coli system to
test its effect on engineered curcumin biosynthesis and excretion.
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CHAPTER III
Experimental Methods

3.1 Genomic DNA Extraction
Various microbial hosts were screened for putative CoA-ligases from NCBI GenBank.
Four hosts were selected that contained putative FCS- or 4CL-encoding genes, including
Acinetobacter sp. NRRL B-65365, Bradyrhizobium japonicum USDA 6, Bradyrhizobium
diazoefficiens USDA 110, Photorhabdus luminescens DSM 3368, and Streptomyces coelicolor
A3(2). These strains were kindly provided by the USDA Agricultural Research Service Culture
Collection (NRRL), except P. luminescens DSM 3368, which was obtained from the German
Collection of Microorganisms and Cell Cultures GmbH. The gene locii for each of these genes is
provided in Table 3.1.
Table 3.1: Gene locii and corresponding protein accession numbers of the CoA-ligase genes used in this study.

Putative
Gene
Function
feruloylCoA
synthase
feruloylCoA
synthase
feruloylCoA
synthase
feruloylCoA
synthase
long chain
fatty acidCoA ligase
acyl-CoA
synthetase

Host

Gene Locus

GenBank Accession
No.

Acinetobacter sp. NRRL B-65365

81081…82958

LRPD01000078.1

B. japonicum USDA 6 (NRRL B-4507)

8788704…8790587

AP012206.1

B. diazoefficiens USDA 110 (NRRL B-4361)

476513…478369

CP011360.1

B. diazoefficiens USDA 110 (NRRL B-4361)

7919197…7921080

CP011360.1

P. luminescens DSM 3368

829567…831255

JXSK01000001.1

S. coelicolor A3(2)

2622582…2624036

AL645882.2
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The genomic DNA (gDNA) from each of the hosts were obtained using a phenol extraction
method. First, each strain was cultivated in 4 mL of the appropriate medium as displayed in
Table 3.2 below.
Table 3.2: Culture media used for obtaining gDNAs

Host

Culture Medium

A. aldaricivorans NRRL B-65365

Tryptone-Yeast Extract
Glucose (TGY)

B. japonicum NRRL B-4507

Modified Arabinose
Gluconate (MAG)

B. japonicum NRRL B-4361

Modified Arabinose
Gluconate (MAG)

B. japonicum NRRL B-4361

Modified Arabinose
Gluconate (MAG)

P. luminescens DSM 3368

Yeast-Malt Extract
(YM)

Each culture was then pelleted and washed with Tris-EDTA (TE) buffer. Phenol and
chloroform extractions were used to remove impurities and aggregate cell lysate at the interface,
and each time the aqueous phase (gDNA-containing) was collected until pure gDNA was obtained,
which was confirmed by gel electrophoresis using agarose gels containing ethidium bromide for
visualization of DNA by UV-Vis excitation.
3.2 Identification and Cloning of Putative FCS Genes from Various Hosts
The target genes were cloned using the polymerase chain reaction (PCR) with primers
designed to probe for the genes of interest. The sequences for each of the primers used are
displayed in Table 3.3. The general reaction scheme for this process is shown in Table 3.4. The
primers were ordered from Thermo Scientific and dissolved in Tris-EDTA (TE) buffer to the
concentration of 100 ng/mL. Phusion High-Fidelity DNA polymerase was purchased from New
England Biolabs. PCR was conducted with an Arktik Thermal Cycler (Thermo Scientific).
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Table 3.3: Primers and plasmids used in this thesis
Gene name

Primers

65365tfcs-F-NdeI

5'-ATCGCATATGAAAGAAATGCAAATGAATGC-3'

65365tfcs-R-PacI

5'-ATCGTTAATTAATTATTGCTTTAAGGTGGGCAC-3'

USDA6tfcs-F-NdeI

5'-ATCGCATATGAGCGGACAGCCGTCCTCTTC-3'

USDA6tfcs-R-KpnI

5'-ATCGGGTACCTTACCCGACCGATATCACACGGTCTG-3'

4361tfcs1-F-NdeI

5'-ATCGCATATGACAGCCGCCTTACGCGGTGACG-3'

4361tfcs1-R-PacI

5'-ATCGTTAATTAATCACCCGACGCACCCAATCCAC-3'

4361tfcs2-F-NdeI

5'-ATCGCATATGAATGCACAGCCGTCCTCTTCC-3'

4361tfcs2-R-PacI

5'-ATCGTTAATTAATTAGCCGACCGATATCACACG-3'

3368stlB-NcoI-NdeI-F

5'-TTAACCATGGGCCATATGTTGGAGAAAGTCTGGCTAAAAC-3'

3368stlB-XhoI-R

5'-AATTCTCGAGTCAGGCTACAGCTACATTCCTGACC-3'

dcs-NdeI-F

5'-ATCGCATATGGAAGCAAATGGTTATCG-3'

dcs-BamHI-R
Plasmid

5'-ATCGGGATCCTTAATTCAGACGGCAGCTATG-3'
Description

pJET1.2

Cloning vector

pET28a(+)

Expression vector

pACYCDuet-1

Expression vector

pCDFDuet-1

Expression vector

pET-16b

Expression vector

pSW54

4cl1 in pACYCDuet-1

pSW24

cus in pET28a(+)

pFZ4

3368stlB in pJET1.2

pJZ164

ScMatB in pET28a(+)

pCB7

65365tfcs in pJET1.2

pCB8

65365tfcs in pACYCDuet-1

pCB9

4361tfcs1 in pJET1.2

pCB10

4361tfcs1 in pAYCYDuet-1

pCB11

4507tfcs in pJET1.2

pCB12

4507tfcs in pAYCYDuet-1

pCB13

4361tfcs2 in pJET1.2

pCB14

4361tfcs2 in pACYCDuet-1

pCB19

4cl1 from pSW54 in pET28a(+)

pCB20

4507tfcs in pET28a(+)

pCB21

HoST in pET-16b

pCB22

Codon-optimized dcs-containing fragment synthesized by GeneUniversal

pCB23

stlB from pFZ4 in pACYCDuet-1

pCB24

Codon-optimized dcs in pJET1.2

pCB25

Codon-optimized dcs in pET-16b

pCB26

Codon-optimized curs1 in pET28a(+)

pCB27

cus in pCDFDuet-1

pCB28

ScMatB from pJZ164 in pACYC-Duet1
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Table 3.4: General PCR Reaction Scheme

Sterilized ddH2O

14.2 µL

High fidelity buffer

4.0 µL

DMSO

0.6 µL

100 mmol dNTPs

0.4 µL

Forward primer

0.2 µL

Reverse primer

0.2 µL

Genomic DNA template

0.2 µL

Phusion DNA polymerase

0.2 µL

Total Volume

20 µL

3.3 Plasmid Construction, Transformation, and Purification
Cloning plasmids for each PCR product were constructed by purifying the blunt-ended
PCR product using the GeneJET PCR purification kit (Thermo Scientific, USA). The purified PCR
product was ligated to pJET1.2/blunt (Thermo Scientific, USA) using the ligation reaction scheme
shown in Table 3.5.
Table 3.5: Ligation Reaction Scheme

pJET1.2/blunt vector

0.3 µL

Purified PCR product

8.0 µL

10X T4 DNA Ligase Buffer

1.0 µL

T4 DNA Ligase

0.7 µL

Total Volume

10 µL

Following ligation, plasmids were transformed into E. coli XL-1-blue using CaCl2
chemical competent cells with heat shock, and the resulting transformation mixture was plated on
LB-agar plates containing the appropriate antibiotic selection marker. Overnight incubation at
37℃ allowed for the formation of visible colonies, which were picked into 4 mL liquid cultures
for outgrowth at 37℃ and 250 rpm for 16 hours.
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Plasmids were purified from the 4 mL liquid cultures using the GeneJET Plasmid
Purification Kit following the manufacturer’s protocol. Plasmids were then visualized by gel
electrophoresis using agarose gels containing ethidium bromide for visualization by UV excitation.
Plasmids were confirmed first by restriction digest using the appropriate restriction endonucleases
to excise the insert, and in cases where function was not able to be confirmed phenotypically,
plasmids were sequenced to confirm the insert was correct.
In the case of pCB21, pCB22 and pCB26, plasmids were directly synthesized by Gene
Universal with codon-optimized inserts for bacterial expression. pCB22 synthesis was not
successfully completed and was therefore used as the PCR template for obtaining the codonoptimized dcs gene for amplification. The PCR product was ligated into pJET1.2/blunt, giving rise
to pCB24, and the gene was then cloned into pET-16b for expression (pCB25). A summary of all
plasmids is shown in Table 3.3 above.
3.4 Induction of Expression
Expression systems were developed using co-transformation by electroporation.
Electrocompetent E. coli cells were prepared using ddH2O and 10% glycerol (v/v) washes to
remove any salts. Electro-transformation of 2-4 plasmids was achieved using a 2.5 kV pulse
applied over 5 msec. Immediately after the pulse, the cells were recovered in 1mL LB broth and
cultured at 37℃ and 250 rpm for 1 hour. The resulting transformation mixture was plated on LBagar plates containing the appropriate antibiotic selection markers corresponding to the cotransformed plasmids. Incubation overnight at 37℃ facilitated the formation of visible colonies,
which were picked into 4 mL liquid seed cultures. The 4 mL TB seed cultures were then outgrown
for 16 hours at 37℃ and 250 rpm.
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After outgrowth, flasks containing 50 mL TB and the working concentration of the
appropriate antibiotics were inoculated using 1% v/v seed culture. The cultures were grown to an
OD600 = 0.7 – 0.9, and expression was induced by the addition of 0.1 mM IPTG after cooling the
cultures to 4℃. The cultures were then transferred to a 28℃ and 250 rpm incubating shaker for
expression. Five hours following the addition of IPTG, 2 mM ferulic acid and 1% v/v glycerol
were added as substrates, and biotransformation of ferulic acid to curcumin was allowed to proceed
for 63 hours post-induction.
3.5 Enzyme Purification and Kinetic Assays
The At4cl1 gene was cloned into pET28a(+) between NdeI and XhoI restriction sites
(pCB19) for expression of a His6-tag fusion protein, and 4507fcs genes was likewise cloned
between NdeI and HindIII restriction sites (pCB20). For expression, 200 mL LB cultures in 1 L
flasks containing kanamycin (50 µg mL-1) were inoculated with 1% v/v overnight seed cultures
and grown to an OD600 of 0.4 - 0.6. Protein expression was induced after cooling to 4℃ by the
addition of 200 µM IPTG, and the flasks were transferred to incubators at 18℃ and 250 rpm for
around 20 hours. The cultures were then pelleted by centrifugation at 3,000 × g and 4℃ for 10
min and resuspended in cold lysis buffer (20 mM Tris-HCl buffer (pH 7.9) and 0.5M NaCl with 1
mM dithiothreitol). Cell disruption was achieved using ultrasonication (Misonix Sonicator 3000,
Misonix Inc., USA) on ice. The lysate was centrifuged at 10,000 × g and 4℃ for 10 min to collect
the soluble fraction containing the target proteins which was analyzed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE analysis used a pre-stained protein
latter (EZ-RunTM Pre-Stained Rec Protein Ladder, molecular range: 11-170 kDa, Fisher
BioReagents) as the reference. After electrophoresis, the gel was stained with 0.1% Coomassie
Brilliant Blue R250, and destained in 20% (v/v) acetic acid-water.
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Enzyme purification was achieved by binding the supernatant from the cell lysates onto a
HisPurTM Ni-NTA agarose affinity column (Thermo Scientific, Rockford, USA) according to the
manufacturer’s protocol. The column was washed with cold (4℃) washing buffers (50 mM TrisHCl, 2 mM EDTA, 10 mM, 25 mM, and 250 mM imidazole, pH 7.9) and the recombinant proteins
were concentrated from the 25 mM and 250 mM imidazole fractions by buffer A (50 mM TrisHCl, 2 mM EDTA, pH 7.9) using the 30,000 MWCO Macrosep Advance Centrifugal Device (Pall
Corporation, New York, USA). The enzymes were suspended in 50% glycerol (v/v) and stored at
-20℃. The protein concentration was determined using the Bio-Rad Quick StartTM Bradford
Protein Assay (Hercules, CA, USA) following the manufacturer’s protocol.
Enzyme kinetics assays were performed for both At4CL1 and 4507FCS purified enzymes.
The reaction mixture (500 µL) contained 5 µg purified protein, 7 mM CoA, and 2 mM ATP in 100
mM potassium phosphate buffer. Ferulic acid was also present in concentrations ranging from 0.1
– 6.6 mM. The reaction was initiated by the addition of 5 µg enzyme and was incubated at room
temperature for 20 minutes. The reaction was quenched using 1 mL methanol, and all 1.5 mL of
the reaction mixture was loaded to a clean 1 cm cuvette. Change in absorbance at 345 nm was used
to quantify the formation of feruloyl-CoA using the reported molar absorptivity of feruloyl-CoA
of 19,000 M-1 cm-1.81 The resulting concentration of feruloyl-CoA was then calculated using the
Beer-Lambert law. Since both enzymes exhibited Michaelis-Menten kinetic behavior, kinetic
parameters were determined by plotting the data on a double-reciprocal (Lineweaver-Burke) plot.
3.6 Product Isolation and Quantification
Curcumin titer was quantified using a whole broth concentration method. Briefly, 2 mL of
well-mixed whole broth were dried under reduced pressure and recovered in 1 mL 50/50 dimethyl
sulfoxide-methanol. Sonication homogenized the concentrated whole broth and facilitated cell
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lysis, and the resulting sample was centrifuged at 15,000 rpm for 10 minutes in preparation for
HPLC analysis. From the supernatant, 100 µL were injected to HPLC and subjected to
chromatographic and UV-Vis absorbance analysis. Curcumin was detected using a 420 nm
wavelength and eluted at 28 min when operating in gradient mode with methanol-water as the
mobile phase (5:95 to 95:5 over 35 min, v/v, containing 0.1% formic acid) with a 1 mL/min flow
rate. ESI-MS spectra were acquired using an Agilent 6130 single quadrupole LC-MS system in
the negative mode to confirm the molecular weights of the curcuminoid products, except for
dicinnamoylmethane, which was confirmed by ESI-MS operating in the positive mode due to its
chemical structure.
For experiments comparing the intracellular and extracellular yields, the whole broth
concentrates (CWB) were obtained together with cell-free fermentation broth concentrates (CFB).
CWB samples were used to determine the total curcumin yield, while CFB samples represented
the extracellular curcumin yield. The “extracellular fraction” of curcumin was determined using
the simple equation:
𝑚𝑔
𝐶𝐹𝐵 𝑇𝑖𝑡𝑒𝑟 [ 𝐿 ]
𝐸𝑥𝑡𝑟𝑎𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛 =
𝑚𝑔
𝐶𝑊𝐵 𝑇𝑖𝑡𝑒𝑟 [ 𝐿 ]
The CFB samples were obtained by centrifuging all 50-mL culture at 3,500 rpm for 5 minutes to
pellet the cells, and 4 mL of the resulting supernatant were dried under reduced pressure and
recovered in 1 mL of 50/50 dimethyl sulfoxide-methanol. As before, the samples were sonicated
and spun in preparation for HPLC, where 100 µL of the final supernatant were loaded to HPLC
for analysis.
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3.7 Statistical Methods
In the case of all yield experiments, samples were collected in triplicate for each treatment
group. The data were fitted with one-way ANOVA using the SAS On Demand online environment.
Pairwise comparisons were made between each treatment group using the Tukey-Kramer
adjustment to control the family-wise error rate, or, as appropriate, comparisons were only made
against the control using the Dunnett’s adjustment. Differences were considered significant only
for p < 0.05 in all cases. Response variables are reported as mean titer ± standard deviation (SD)
in mg L-1.
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CHAPTER IV
Results

4.1 Identification of an Efficient FCS from Bradyrhizobium japonicum USDA 6
Screening of various putative CoA-ligases showed that several indeed encode functional
proteins exhibiting feruloyl-CoA synthase (FCS) activity. Functional screening was confirmed by
co-expression of the putative CoA-ligase-encoding plasmid with pSW24 that harbors the
curcuminoid synthase (CUS). Curcumin formation was obvious based on the yellowing of the
culture broth, and HPLC analysis confirmed the presence of curcumin in several samples. Only
pCB28, encoding ScMatB, did not shown any FCS activity. The native function of ScMatB is to

Figure 4.1: HPLC analysis using 420 nm to detect the formation of curcumin when each FCS-encoding construct was coexpressed with CUS. pACYCDuet-1 served as a negative control, and pSW54 served as the positive control.
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convert malonate to malonyl-CoA, so the lack of substrate flexibility toward ferulic acid is likely
due to the phenolic ring causing steric hindrance in the active site of ScMatB. Stacked HPLC
chromatograms compared to a negative control (blank pACYCDuet-1 + pSW24) and a positive
control (pSW54 + pSW24) are displayed in Figure 4.1.
In the interest of making a statistically relevant yield comparison between each of the
functional FCSs, expressions were performed in triplicate for each under the same expression
conditions as before. Comparisons were made for each “high productivity” FCS-encoding plasmid
against pSW54 (encoding At4CL1 commonly used for heterologous curcumin biosynthesis). High
productivity FCSs were determined loosely based on peak area and included the FCSs encoded in
pCB8, pCB12, pCB14, and pKH4. The results revealed that the FCS encoded in pCB12 (the FCS
from B. japonicum USDA 6 B-4507) could potentially improve yield compared to At4CL1,
improving the yield from 13.99 ± 0.67 µg/mL to 17.37 ± 3.23 µg/mL (Fig. 4.2).

Figure 4.2: Curcumin yield comparisons of each FCS. Left: Bar graphs showing mean curcumin production ± SD for each FCS
in mg L-1. Right: Statistical grouping (Tukey-Kramer) of FCSs based on curcumin yield. H indicates high productivity, M indicates
moderate productivity, and L indicates low productivity. FCSs with the same grouping are not significantly different from each
other at the p < 0.05 significance level.
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Though the difference between 4507FCS and At4CL1 was not significantly different,
4507FCS was the only FCS categorized solely as a “high” curcumin producer, encouraging us to
further investigate this enzyme for use in the curcumin biosynthetic pathway. We hypothesize that
since 4507FCS is a dedicated bacterial enzyme, it may exhibit improved enzymatic activity over
the plant At4CL1 in a bacterial production system. It is important to mention that the overall
curcumin yield was low, as is common when using CUS as the condensing enzyme in the
biosynthetic pathway.65
4.2 Kinetic Parameters of 4507FCS v. At4CL1 in vitro
Due to the observed increase in yield using 4507FCS compared to At4CL1, we were
encouraged to isolate these enzymes for in vitro kinetic analysis. Each enzyme was successfully
purified to near homogeneity by Ni-NTA Agarose resin column chromatography using increasing
concentrations of imidazole in the mobile phase. The purified proteins were then confirmed by
loading 1 µL of the pure enzyme stock to SDS-PAGE. Both purified proteins were approximately
70 kDa in size (Fig. 4.3).

Figure 4.3: SDS-PAGE analysis of purified At4CL1 (1) and 4507FCS (2) compared to
protein standards (M).

25

Based on the SDS-PAGE results, At4CL1 had substantially better expression over
4507FCS. The isolated yields were calculated for each enzyme using a Bradford assay to make a
quantitative comparison between the expression level. The stock concentrations of 4507FCS and
At4CL1 were determined to be 371.0 mg L-1 and 6193.4 mg L-1, respectively. These stock
concentrations were used to determine the total protein yield from the 200 mL LB expression
system, which were found to be 1.855 mg L-1 for 4507FCS and 30.967 mg L-1 for At4CL1,
indicating that At4CL1 may have over 16 times higher expression levels than 4507FCS when
expressed in E. coli.
Kinetic assays revealed that both proteins exhibited Michaelis-Menten style kinetics,
allowing for the determination of the enzymatic kinetic constants by plotting the data on a double
reciprocal (Lineweaver-Burke) plot (Fig. 4.4).

Figure 4.4: Lineweaver-Burke Plots for At4Cl1 (left) and 4507FCS (right)

The linear regression data were then used to calculate the key kinetic parameters for these
two enzymes, which are displayed below in Table 4.1. It was revealed that 4507FCS exhibited
improved enzymatic activity over At4CL1, with a net 73% improvement in kcat/Km. Specifically,
the enzyme exhibited improved catalytic efficiency, with a kcat of 0.767 s-1 compared to the
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At4CL1 kcat of 0.074 s-1. Interestingly, the Km of 4507FCS was higher than that of At4CL1,
suggesting that the enzyme may not be as efficient for binding the substrate under low substrate
concentrations. High ferulic acid concentrations (exceeding 2 mM) have been avoided in other
studies to avoid substrate toxicity to the production host, indicating that excess ferulic acid may
negatively impact E. coli. One method to circumvent this issue is the addition of 2 mM at the
beginning of the fermentation run, followed by the addition of 1mM ferulic acid 15 hours later,
rather than adding all 3 mM at the beginning of the run.64
Table 4.1: Enzyme kinetics for At4CL1 and 4507FCS

Kinetic Parameter

At4CL1

4507FCS

% Change

[E] (µM)

0.06

0.05

-

Vmax (µM min-1)

0.26

2.25

+765%

Km (µM)

101.4

608.0

+500%

kcat (s-1)

0.074

0.767

+936%

kcat /Km (M-1 s-1)

728.3

1261.1

+73%

4.3 Investigation of StlB for Curcuminoid Production
One of the screened proteins that exhibited low FCS activities was StlB, a bacterial CoAligase from P. luminescens DSM 3368 that is involved in bacterial stilbene biosynthesis. StlB has
the native function of catalyzing the conversion of cinnamic acid to cinnamoyl-CoA, which is used
as a precursor for the formation of 3,5-dihydroxy-4-isopropyl-trans-stilbene, commonly known as
Benvitimod or Tapinarof.82,83 To investigate the substrate flexibility of StlB for the formation of
various curcuminoids, an StlB-encoding construct (pCB23) was co-transformed with pSW24,
encoding CUS. Several expression cultures were used to test the effect of different substrates to
screen for the formation of various curcuminoids. Based on the corresponding curcuminoids
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formed, it was found that StlB exhibits strong cinnamoyl-CoA synthase activity, as well as weak
FCS and p-coumaroyl-CoA ligase activity. However, StlB cannot take caffeic acid as a substrate
for the formation of caffeoyl-CoA. A summary of the HPLC-MS data used to confirm the
formation of these products is displayed in Table 4.2.
Table 4.2: Summary of StlB substrate flexibility testing. n.d. indicates no data obtained due to extremely low activity.

Substrate

ferulic acid

p-coumaric acid

caffeic acid

cinnamic acid

StlB + CUS Product

At4CL1
Peak
Area

StlB
Peak
Area

Deduced
StlB
CoALigase
Activity

366.9
[M-H]-

43765.0

235.8

Weak

306.9
[M-H]-

12895.1

2623.2

Weak

n.d.

6106.5

n.d.

None

277.0
[M+H]+

12903.6

20948.3

Strong

ESI-MS Data
(m/z)

curcumin

bisdemethoxycurcumin

dicaffeoylmethane

dicinnamoylmethane

Detailed chromatograms, ESI-MS spectra, and UV-Vis spectra for each of the data points
contained in Table 4.2 are displayed in Appendix A.
4.4 Optimization of the Curcumin Biosynthesis Enzymatic Approach
In plants, two common biosynthetic pathways are commonly used for producing curcumin,
as depicted previously in Figure 2.2. These two pathways have been studied extensively, and it is
generally understood that the use of 4CL and CUS alone yields less curcumin than the 4CL, DCS,
and CURS1 approach. However, no work to our knowledge has been conducted to elucidate the
exact limiting step in the curcumin biosynthetic pathway. To address this issue, we used the
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efficient 4507FCS identified previously, to make comparisons on four enzymatic approaches for
achieving curcumin biosynthesis were evaluated for productivity. The four enzymatic approaches
tested are summarized in Table 4.3.
Table 4.3: Enzymatic approaches for achieving curcumin biosynthesis investigated in this thesis.

No.
1
2
3
4

Enzyme Combination
FCS + CUS
FCS + DCS + CURS1
FCS + DCS + CUS
FCS + DCS + CUS + CURS1

Plasmids Used
pCB12 + pSW24
pCB12 + pCB25 + pCB26
pCB12 + pCB25 + pSW24
pCB12 + pCB25 + pCB26 + pCB27

Each of the enzymatic approaches was constructed by co-transformation of the appropriate
plasmids and expressed in triplicate. All possible pairwise comparisons were made on the resulting
yields to demonstrate which combination of enzymes provided the best curcumin yield. The
average yields, reported as mean yield ± standard deviation in mg L-1, for each of the approaches
are presented in Table 4.4.
Table 4.4: Mean curcumin yields for each enzymatic approach

No. Mean Curcumin Yield ± SD (mg L-1)
1
15.5 ± 0.7
2
104.7 ± 12.6
3
73.0 ± 11.1
4
118.0 ± 1.6
There are four key findings from this experiment. First, we confirmed that the efficacy of
CUS alone is far inferior to that of DCS + CURS1, as made evident by the large curcumin yield
difference between approaches 1 and 2. This comparison had generally been understood in
previously reported literature, but no exact yield data had been tied to the approaches.
Second, it was found that DCS is the key determining factor for improving curcumin
production in E. coli. This can be deduced by the significant yield improvement in the DCS-
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containing combinations (2 – 4) compared to approach 1. Special interest should be placed on the
large yield improvement between approaches 1 and 3, which demonstrates that the rate-limiting
step in the curcumin biosynthetic pathway is the formation of feruloyldiketide-CoA from feruloylCoA and malonyl-CoA. Addition of DCS to approach 1 improved the yield from 15.5 ± 0.7 to 73.0
± 11.1 mg L-1, corresponding to a 4.7-fold improvement in curcumin yield.
Third, within the DCS-containing group, it was further demonstrated that CURS1 is a more
efficient condensing enzyme than CUS, as made evident based on the observed increase in yield
between approaches 2 and 3. The use of CURS1 improved curcumin yield from 73.0 ± 11.1 to
104.7 ± 12.6 mg L-1, corresponding to a 1.5-fold improvement.
Finally, we demonstrated that the full construction of both enzymatic approaches as
achieved in approach 4 further enhances the yield over approach 2 and 3. Though no significant
difference was observed between approaches 2 and 4, the trend is fascinating considering the
increased metabolic burden imposed on E. coli in approach 4 over approaches 2 or 3. These data
suggest that the full construction of both pathways has a positive impact on curcumin production,
as the pathways mutually build the metabolic intermediate pools.

Figure 4.5: Curcumin yield comparisons for enzymatic approaches 1 through 4. **** indicates p < 0.0001, *** indicates p <
0.001, ** indicates p < 0.01, and ns indicates no significant difference.
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Each of these comparisons and the strength of the statistical significance between each
group may be visualized in Figure 4.5.
4.5 Glycosylation of Curcumin In Vivo
Simultaneous production and glycosylation of curcumin was performed by the coexpression of the curcumin biosynthetic enzymes encoded in pCB12 and pSW24 together with
either the novel fungal glucosyltransferase (BbGT) or bacterial UDP-glucuronyltransferase
(UGT), encoded in pCB15 and pCB16, respectively. Previously, when added as an exogenous
substrate to the expression culture, curcumin could not be glycosylated (data not shown). We
theorize that glycosylation could not occur since curcumin is practically water insoluble84 and does
not readily traverse the cell wall of E. coli, thus separating the curcumin substrate from the
enzymes across the cell wall. Interestingly, when BbGT and UGT were co-expressed with the
curcumin biosynthetic enzymes, both glucosylation and glucuronidation of curcumin were
achieved, as confirmed by the formation of glucosylated and glucuronidated curcumin products.
The curcumin glucoside had a retention time of 20.5 minutes, which was 3.5 minutes earlier
than curcumin, which eluted at 24 minutes using a gradient mode HPLC method with methanolwater as the mobile phase (20:80 to 95:5 over 25 min, v/v, containing 0.1% formic acid) with a 1
mL/min flow rate. The UV-Vis spectrum of the glucoside was similar to that of curcumin, which
suggested that the product shared the same core structure. ESI-MS spectra has not yet been
successfully captured for the glucosylated product, which is typically produced in very low titers
(Fig. 4.6).
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B

A

Figure 4.6: Formation of curcumin and curcumin glucoside by E. coli BL21(DE3) / pCB12 + pSW24 + pCB15. (A) HPLC
chromatogram measuring absorbance at 420 nm, showing two peaks corresponding to curcumin (1) and curcumin glucoside (2);
(B) Overlayed UV-Vis spectra of peaks 1 and 2.

The glucuronidated curcumin product had a retention time of 12.5 minutes, suggesting an
improvement in water solubility compared to curcumin, which eluted at 17 minutes. The HPLC
method used a 420 nm wavelength and gradient mode operation with methanol-water as the mobile
phase (45:55 to 95:5 over 25 min, v/v, containing 0.1% formic acid) with a 1 mL/min flow rate.
The UV-Vis spectrum of the glucuronide was very similar to that of curcumin, suggesting
similarity in core structure, and the molecular weight was confirmed by ESI-MS to be curcumin
monoglucuronide based on the addition of 176 g mol-1 for a total mass of 544 g mol-1. These data
are all displayed below in Figure 4.7.

32

B

A

C

D

Figure 4.7: Formation of curcumin and curcumin glucuronide by E. coli BL21(DE3) / pCB12 + pSW24 + pCB16. (A) HPLC
chromatogram showing the simultaneous production of curcumin (1) and curcumin glucuronide (3); (B) Overlayed UV-Vis spectra
of peaks 1 and 3 suggest a similar core structure; (C) ESI-MS spectra for peak 3, confirming curcumin monoglucuronide product;
(D) ESI-MS spectra for peak 1, confirming curcumin production.

4.6 Sulfation of Curcumin In Vivo
The Haliangium ochraceum DSM 14365 sulfotransferase (HoST) (from gene locus
Hoch_5094, GenBank Accession No. CP001804.1) was selected as a target enzyme for sulfating
curcumin in vivo. HoST was selected as a target enzyme due to its reported versatility for the
sulfation of small molecules. Specifically, HoST is an aryl sulfotransferase that exhibits broad
substrate specificity within the phenolic compound family and works especially well for the
sulfation of symmetrical phenolics such as 4,4′-biphenol.85 Since curcumin is also a symmetrical
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biphenolic molecule, we hypothesized that HoST could be an excellent enzyme target for curcumin
sulfation in vivo.
To determine if HoST could accept curcumin as a substrate, HoST was first expressed
alone in E. coli BL21(DE3). The same expression conditions were utilized as with other expression
experiments, but 10 mg of curcumin were supplemented as substrate 5 hours after the addition of
0.2 mM IPTG. The fermentation broth was then sampled after 24 hours of biotransformation.
HPLC-MS analysis conducted on 100 µL of cell-free fermentation broth revealed the formation of
curcumin sulfate, with a molecular mass of 448 g mol-1, confirmed by ESI-MS. The UV-Vis
spectra of curcumin and curcumin sulfate were also highly similar, suggesting a similar molecular
core structure (Fig. 4.8).
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C

Figure 4.8: Biotransformation of curcumin into curcumin sulfate by E. coli BL21(DE3) / pCB21. (A) HPLC chromatogram showing
the formation of curcumin (1) and curcumin sulfate (2); (B) Overlayed UV-Vis spectra of peaks 1 and 4 suggest a similar core
structure; (C) ESI-MS of peak 4 demonstrates that HoST can accept curcumin as a substrate for the formation of curcumin sulfate,
as indicated by the addition of 80 g mol-1 to curcumin (368 g mol-1).

After confirming that HoST indeed accepts curcumin as a substrate, we were encouraged
to attempt curcumin production with simultaneous expression of HoST to allow for sulfation of
curcumin as it is produced for eventually modulating curcumin excretion. A time course
experiment was conducted to identify the best biotransformation period to maximize the
production of curcumin and curcumin sulfate. As might be expected, curcumin peak area decreased
over time while curcumin sulfate peak area increased as curcumin was bio-transformed into its
sulfated conjugate (Fig. 4.9).
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Figure 4.9: Curcumin sulfate production is inversely proportional to curcumin production over time

The sulfated product in the co-expression system exhibited a reduced retention time
compared to when HoST was expressed alone. HPLC-MS analysis revealed that the co-expression
sulfation product had a molecular mass of 528.3 g mol-1, representing the addition of 160 g mol-1
to the curcumin mother structure. These data suggest that in the co-expression system, curcumin
can be sulfated on both phenolic rings, likely in a stepwise fashion, to yield curcumin disulfate.
The UV-Vis spectra of the di-sulfated product was not significantly different from that of
curcumin, again suggesting that the core structure was preserved (Fig. 4.10).
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Figure 4.10: Curcumin di-sulfate was obtained when curcumin biosynthetic enzymes were co-expressed with HoST in E. coli.
(A) HPLC chromatogram showing the retention times of curcumin (1) and curcumin disulfate (5); (B) Overlayed UV-Vis spectra
of 1 and 5 demonstrate similarity, suggesting a similar core structure; (C) ESI-MS spectra of peak 5 revealed that the product
was indeed curcumin disulfate.

4.7 Effect of Transferase Co-Expression on Curcumin Excretion
We next aimed to improve curcumin excretion to pave the way to continuous fermentation
systems. Three transferases were investigated: a fungal glucosyltransferase from Beauveria
bassania ATCC 7159 (BbGT), a bacterial UDP-glucuronyltransferase from Streptomyces
chromofuscus ATCC 49982 (UGT), and a sulfotransferase from Haliangium ochraceum DSM
14365 (HoST). In the interest of minimizing metabolic burden by the co-expression of several
plasmid DNAs, each transferase was expressed with FCS and CUS rather than FCS, DCS, and
CURS1, exchanging metabolic burden for decreased curcumin production efficiency. Triplicate
expressions in TB clearly demonstrated that each transferase indeed improves excretion based on
extracellular curcumin fraction. Comparisons against FCS and CUS alone revealed that BbGT co-
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expression most significantly improves extracellular curcumin fraction, improving the mean
extracellular fraction from 31.0 ± 1.8% to 46.1 ± 1.0% (p = 0.0025), corresponding to an overall
48.7% improvement in curcumin excretion (percent change). The use of UGT and HoST also
significantly improved excretion, yielding extracellular curcumin fractions of 40.2 ± 2.1% and
40.5 ± 5.7%, respectively (Fig. 4.11).

Figure 4.11: Fraction of total curcumin yield obtained from the cell-free culture medium (“extracellular fraction”) grouped by the
transferase co-expressed with curcumin biosynthetic enzymes.

We were interested in knowing whether curcumin glycosides and curcumin sulfate existed
predominantly in the extracellular fraction, consistent with our theory that glycosylation and
sulfation can promote excretion from the cell. However, when expressed in TB with glycerol as a
carbon source, very little glycosidic and sulfated products were detected, complicating the
analysis. To attempt to extend induced expression time, we attempted expression in LB with the
addition of ferulic acid 5 hours after induction by the addition of 0.1 mM IPTG and the delayed
addition of glucose 18 hours after the addition of IPTG. These measures were implemented to
attempt to postpone the deactivation of the lac operon contained in our expression constructs. We
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were able to see marked improvements in curcumin glycoside and sulfated product peak areas,
indicating that the delayed addition of glucose can boost the production of curcumin glucoside,
curcumin glucuronide, and curcumin sulfate. We next compared the peak area data for each
glycoside, glucuronide, and sulfated product from the LB expression experiment to determine the
predominant location of each of the products. These data are presented in Table 4.5.
Table 4.5: Curcumin glycoside and sulfate product peak areas when expressed in LB with delayed addition of glucose.

Transferase

CFB Peak Area

CWB Peak Area

Extracellular Fraction

(mAU*s)

(mAU*s)

BbGT

76.9 ± 61.1

79.2 ± 58.5

49.30%

UGT

568.4 ± 118.5

412.2 ± 144.5

58.00%

HoST

12.7

9.4

57.50%

To better visualize the effect of transferase co-expression on curcumin excretion, we
analyzed the location of curcumin, curcumin-x (where x represents glucoside, glucuronide, or
sulfate), and “total curcumin” (the sum of curcumin and curcumin-x) for each expression system.
Then, using the average peak areas for each treatment group, we calculated the mean extracellular
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fraction as a ratio of the average CFB peak area over the average CWB peak area and plotted these
as stacked columns for each curcumin, curcumin-x, and total curcumin (Fig. 4.12).
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Figure 4.12: Visual representation of curcumin excretion based on transferase co-expression. (A) Curcumin extracellular fractions
stacked on intracellular fractions; (B) Modified curcumin products (“curcumin-x”) extracellular fractions stacked on intracellular
fractions; (C) Total curcumin extracellular fractions stacked on intracellular fractions.

This analysis demonstrated visually that the curcumin-x products indeed existed
predominantly in the extracellular culture medium except for curcumin glucoside, which existed
approximately half as an intracellular metabolite and half as an extracellular metabolite. Overall,
the expression of UGT had the strongest impact on total curcumin excretion under the LB
expression conditions.
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4.8 Effect of Transferase Co-Expression on Total Curcumin Yield
Though the effect of curcumin excretion was well established for each transferase, the
overall impact on yield was also investigated using the same TB expression system data obtained
in section 4.7. Using the CWB titer as the “total curcumin” yield in the system with comparisons
to FCS+CUS as the control, it was shown that curcumin yield was decreased in the case of each
transferase treatment group (Fig. 4.13).

Figure 4.13: Total curcumin yield in mg L-1 for each transferase treatment group.

The co-expression of BbGT with the curcumin biosynthetic enzymes had the strongest
negative impact on curcumin production, while UGT and HoST had similar negative effects on
curcumin production. Likely, this phenomenon can be explained in part by increased metabolic
burden imposed on the cells by the co-expression of an additional enzyme. However, our group
previously reported that UGT could accept ferulic acid as a substrate for the formation of ferulic
acid-4-O-β-D-glucuronide.78 This understanding gave rise to an alternative hypothesis that some
ferulic acid was being glycosylated or sulfated prior to entering the curcumin biosynthetic
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pathway, which may have sterically restricted its entry into the FCS and/or CUS catalytic domains,
thereby reducing the formation of curcumin (Fig. 4.14).

Figure 4.14: Proposed glycosylation pathways involved in FCS+CUS+BbGT and FCS+CUS+UGT co-expression systems. We
hypothesize that glycosylation of ferulic acid preceding the curcumin biosynthetic steps reduces the formation of curcumin and its
derivatives.

Therefore, we revisited our HPLC data collected for BbGT, UGT, and HoST co-expression
systems, this time using a 300 nm wavelength to scan for ferulic acid and ferulic acid derivatives.
We stacked the resulting HPLC chromatograms obtained from each transferase treatment group
and compared them against the control (FCS+CUS). Indeed, the formation of ferulic acid
derivatives were detected that did not exist in the control for BbGT- and UGT-containing samples.
However, HoST showed no apparent activity toward ferulic acid (Fig. 4.15). ESI-MS data for the
ferulic acid derivatives has yet to be collected, which is an important future step for validating the
hypothesis.
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A

B

C

Figure 4.15: Glycosylation of ferulic acid (6) may be a factor for reducing curcumin productivity. (A) Stacked chromatograms of
each transferase treatment group with FCS+CUS serving as a negative control (“None”). The likely formation of ferulic acid-4O-β-glucoside (7) and ferulic acid-4-O-β-glucuronide (8) are shown with reduced retention times, corresponding to higher water
solubility; (B) Overlayed UV-Vis spectra of peaks 6 and 7 suggest that the product is derived from ferulic acid; (C) Overlayed
UV-Vis spectra of peaks 6 and 8 suggest that the product is derived from ferulic acid.
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CHAPTER V
Conclusions

Herein, several upstream biological engineering methods have been investigated to
improve the heterologous production of curcumin in E. coli. Each of the reported methods
represent an improvement in curcumin yield, expanding the toolbox for future researchers and
industry professionals, thereby improving access to this pharmaceutically relevant compound.
First, we reported the discovery of an efficient FCS that can improve the feruloyl-CoA
precursor metabolite pool. Isolation and in vitro analysis of these enzymes revealed that the FCS
has higher catalytic efficiency but lower binding affinity for the ferulic acid substrate, for a net
improvement in kcat/Km. These findings suggest that the use of 4507FCS can improve curcumin
production under saturation conditions, but that At4CL1 may be the enzyme of choice if lower
concentrations of ferulic acid are utilized. Furthermore, we demonstrated that though FCS exhibits
higher kcat/Km, the expression levels remain low relative to At4CL1. Further work should seek to
improve 4507FCS expression to build its commercial relevance in the curcumin biosynthetic
pathway. Various methods may be employed to improve 4507FCS expression, including codon
optimization and optimization studies on 4507FCS induction parameters.
The use of FCSs from various hosts paves the way for future researchers to continue FCS
screening to potentially identify other efficient FCSs that can be used not only to achieve curcumin
biosynthesis, but also for the biosynthesis of other compounds that rely on feruloyl-CoA as a
precursor, such as vanillin,86 coumarins,87 and lignans.88 This study focused on a limited number
of FCSs, thus the possibility of discovering another with further improved activity remains a
possibility.
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Direct comparisons on the in vitro enzymatic activities of At4CL1 and 4507FCS elucidated
the mechanism by which 4507FCS improves curcumin biosynthesis, specifically by enhanced
catalytic efficiency. These findings may encourage structural biologists to analyze the key residues
involved in enhancing catalytic efficiency for feruloyl-CoA formation, which may allow for
enzyme engineering and the development of an “ideal” FCS in the coming years.
The importance of DCS in the biosynthetic pathway has been clearly demonstrated in this
thesis, therefore giving clear confirmation that the rate-limiting step in the curcumin biosynthetic
pathway is the formation of feruloyl-diketide-CoA from feruloyl-CoA and malonyl-CoA. The
marked improvement in curcumin biosynthesis in DCS-containing co-expression systems suggests
that the polyketide synthetic domain of CUS responsible for condensing malonyl-CoA with
feruloyl-CoA to form feruloyl-diketide CoA may not be as efficient as that of DCS. However, the
CURS1 appears to have improved condensation activity over CUS for the formation of β-ketoacid
and curcumin from their precursors, as demonstrated by the maximized yield from the
DCS/CURS1 co-expression system. Together, these findings may encourage protein engineers to
develop a fusion protein that brings the catalytic domains of DCS and CURS1 in closer proximity
to test the effect on curcumin biosynthesis, which we hypothesize would have a positive impact
on productivity. Furthermore, these findings demonstrate that the FCS-catalyzed reaction is not
the limiting step in the curcumin biosynthetic pathway, and that more research effort should be
placed on the condensation steps.
To our knowledge, the use of glycosylation and sulfation as reported in this thesis are the
first reported mechanisms for exporting curcumin from the heterologous production host.
Significant improvements in curcumin excretion using these modifications suggest that E. coli may
take advantage of the same detoxification mechanisms observed in human metabolism. These
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findings also represent the first time that BbGT, UGT, and HoST have successfully formed
glycosylated or sulfated curcumin products in an in vivo system, since previous studies only
reported on their activities towards curcumin in vitro. These methods form a basis for the eventual
use of continuous fermentation systems, greatly reducing the cost of curcumin biosynthesis and
increasing the benefits of its heterologous production over agricultural methods. Additionally,
these findings provide a biosynthetic approach to produce more water soluble and bioavailable
forms of curcumin, including curcumin glucoside, curcumin glucuronide, and curcumin sulfate,
with direct applications for human health.
Though the efficiency of the overall curcumin production system was decreased when coexpressing a transferase, we hypothesize that this is in part the effect of increased metabolic
burden, which may be readily circumvented by constructing a plasmid that encodes each of the
needed proteins for curcumin production and glycosylation or sulfation. Additionally, the
curcumin and modified curcumin yields may also be improved by constructing a plasmid carrying
the fcs, dcs and curs1 genes for co-expression with a transferase. In the case of glycosylation, we
also hypothesize that the reduced curcumin production may be the result of substrate glycosylation
prior to entering the curcumin biosynthetic pathway. This issue is not easily resolved but could be
the subject of future enzyme engineering studies. For example, the catalytic domains of FCS and
CUS could be engineered to open wide enough to accept a glycosylated substrate if steric
hindrance is in fact at play.
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CHAPTER VI
Engineering Value and Future Work

6.1 Engineering Value
In this thesis, several engineering approaches have been employed to enhance the
heterologous production of curcumin in E. coli. First, the characterization of several FCSs that
may be used to replace 4CL creates a modular toolbox that may be used not only for the
biosynthesis of curcumin, but also for other valuable bioproducts that require feruloyl-CoA as a
precursor, such as vanillin, lignans, and coumarins. We also elucidated the exact mechanism and
conditions under which 4507FCS improves curcumin biosynthesis over At4CL1, which provides
valuable information for the development of biochemical engineering processes, specifically the
tuning of substrate concentrations to optimize system efficacy.
Furthermore, this work clearly demonstrates the limiting step in the curcumin biosynthetic
pathway, which is the condensation step catalyzed by DCS, which provides a target for future
enzyme engineering and metabolic engineering strategies that may be used to efficiently optimize
curcumin biosynthesis. This limiting step can be viewed as an engineering constraint that ought to
be the focus of future research to expand the possibilities for further yield improvements.
Finally, this thesis provides a method for enzymatically modifying curcumin to improve
its water solubility and allow for improved excretion from the cell. These

advances

provide

biochemical engineers with a tool for the development of continuous fermentation systems that
can greatly reduce the energy, time, and complexity of curcumin downstream processing by
eliminating the need for cell disruption.
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6.2 Future Work
6.2.1 Individual Enzyme Expression Optimization
Little work was performed in this thesis to improve the expression levels of the individual
enzymes participating in the curcumin biosynthetic pathway. Future work should focus on
maximizing the expression of each individual protein in the pathway, then developing a method
that allows for combinatorial curcumin biosynthesis using the method that most appropriately
supports high expression for the enzyme combination selected. Special focus should be placed on
improving 4507FCS expression in E. coli. Potential methods may include codon optimization and
optimization of induction parameters to harness the full potential of this enzyme.
6.2.2 Improving Curcumin Glycoside and Curcumin Sulfate Production
We hypothesize that curcumin glycoside and sulfate production may be greatly enhanced
if DCS and CURS1 are used as the condensing enzymes in place of CUS. In this thesis, we only
explored the use of CUS with the transferase enzymes in the interest of time and minimizing
metabolic burden, but future work could consider the use of a single construct encoding each of
the biosynthetic enzymes needed to achieve simultaneous curcumin production and
glycosylation/sulfation (i.e. FCS, DCS, CURS1, and BbGT on one or two constructs instead of
each being encoded on individual constructs).
Methods should also be implemented to limit the glycosylation of ferulic acid substrate
prior to entering the curcumin biosynthetic pathway. For example, one synthetic biological
approach may employ the use of constitutive promoters for the curcumin biosynthetic genes
together with the use of an inducible promoter for the transferase gene. In this way, the curcumin
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metabolic pool could be built up prior to the induction of the transferase gene to improve the
efficiency of the glycosylation pathways.
6.2.3 Structural Studies and Enzyme Engineering
Much structural information about the key catalytic residues of the enzymes involved in
curcumin biosynthesis is left unexplored in this work. Future studies could compare the catalytic
regions of At4CL1 and 4507FCS for better understanding the key differences that allow for
upregulating the formation of feruloyl-CoA.
Additionally, as we postulated in this thesis, many enzyme engineering applications need
continued study, especially the effect of DCS-CURS1 proximity on productivity. A fusion of these
two enzymes is theorized to improve yield by bringing their catalytic domains closer together to
reduce the diffusion limitations of curcumin metabolic intermediates.
6.2.4 Biochemical Process Development and Optimization
To improve the industrial application of the work performed in this thesis, curcumin
production should be performed in a bioreactor. An appropriate operating mode should be selected
for optimizing curcumin production (batch, fill and draw, continuous, etc.), then different retention
times, substrate concentrations, oxygenation methods, and mixing speeds should be evaluated.
Continuous fermentation systems should be the first target for curcumin production to improve
product consistency, reduce operating costs, and minimize downstream processing. Conditions
should also be optimized to produce curcumin glucoside, curcumin glucuronide, and curcumin
sulfate to improve access to more bioavailable forms of curcumin.
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Additionally, bioreactor studies could consider reducing operating costs by using cheaper
carbon sources, such as crude glycerol arising from biodiesel production to reduce the overall costs
associated with curcumin biosynthesis. Cheaper nitrogen sources may also be tested. For example,
algae has been successfully used in several studies for the denitrification of wastewaters,89–91
yielding nitrogen-rich algae whose lysate could be fed as a nitrogen source to engineered E. coli
for curcumin production.
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Appendix A. Supplemental Spectral Data
for Confirmation of Various Curcuminoids
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Figure A.1: Confirmation of curcumin formation by StlB with (A) retention time analysis, (B) UV-Vis spectral
analysis and (C) ESI-MS spectral analysis
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Figure A.2: Confirmation of bisdemethoxycurcumin formation by StlB with (A) retention time
analysis, (B) UV-Vis spectral analysis and (C) ESI-MS spectral analysis
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Figure A.3: No dicaffeoylmethane formation by StlB + CUS confirmed by retention time analysis shows that StlB cannot
accept caffeic acid as a substrate
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Figure A.4: Confirmation of dicinnamoylmethane formation by StlB with (A) retention time analysis,
(B) UV-Vis spectral analysis and (C) ESI-MS spectral analysis

